HomeDiscoveryPubblicazioniPubblicazioni 2015

Pubblicazioni 2015

2015

 

Editorial: BITS2014, the annual meeting of the Italian Society of Bioinformatics
Facchiano A, Angelini C, Bosotti R, Guffanti A, Marabotti A, Marangoni R, Pascarella S, Romano P, Zanzoni A, Helmer-Citterich M
Bioinformatics (2015), 16(Suppl) 9), S1
View abstract on PubMed

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
Amatu A, Somaschini A, Cerea G, Bosotti R, Valtorta E, Buonandi P, Marrapese G, Veronese S, Luo D, Hornby Z, Multani P, Murphy D, Shoemaker R, Lauricella C, Giannetta L, Maiolani M, Vanzulli A, Ardini E, Galvani A, Isacchi A, Sartore-Bianchi A, Siena S
Br J Cancer. (2015), 113(12), 1730-4
View abstract on PubMed

A Novel High-Content Immunofluorescence Assay as a Tool to Identify at the Single Cell Level γ-Globin Inducing Compounds
Durlak M, Fugazza C, Elangovan S, Marini MG, Marongiu MF, Moi P, Fraietta I, Cappella P, Barbarani G, Font-Monclus I, Mauri M, Ottolenghi S, Gasparri F, Ronchi A.
PLoS One (2015), 10(10), 1-14
View abstract on PubMed

Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening
Anania M, Gasparri F, Cetti E, Fraietta I, Todoerti K, Miranda C, Mazzoni M, Re C, Colombo R, Ukmar G, Camisasca S, Pagliardini S, Pierotti M, Neri A, Galvani A, Greco A.
Oncotarget (2015), 6(33), 34629-34648
View abstract on PubMed

Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy
Papeo G, Posteri H, Borghi D, Busel AA, Caprera F, Casale E, Ciomei M, Cirla A, Corti E, D’Anello M, Fasolini M, Forte B, Galvani A, Isacchi A, Khvat A, Krasavin MY, Lupi R, Orsini P, Perego R, Pesenti E, Pezzetta D, Rainoldi S, Riccardi-Sirtori F, Scolaro A, Sola F, Zuccotto F, Felder ER, Donati D, Montagnoli A
J Med Chem (2015), 58(17), 6875-98
View abstract on PubMed

Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90
Riccardi Sirtori F, Caronni D, Colombo M, Dalvit C, Paolucci M, Regazzoni L, Visco C, Fogliatto G
Eur J Pharm Sci (2015), 30(76), 83-94
View abstract on PubMed

A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
Borthakur G, Dombret H, Schafhausen P, Brummendorf TH, Boissel N, Jabbour E, Mariani M, Capolongo L, Carpinelli P, Davite C, Kantarjian H, Cortes JE
Haematologica (2015), 100(7), 898-904
View abstract on PubMed

Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders
Brasca MG, Gnocchi P, Nesi M, Amboldi N, Avanzi N, Bertrand J, Bindi S, Canevari G, Casero D, Ciomei M, Colombo N, Cribioli S, Fachin G, Felder ER, Galvani A, Isacchi A, Motto I, Panzeri A, Donati D.
Bioorg Med Chem (2015), 15;23(10), 2387-407
View abstract on PubMed

A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
Yu SF, Zheng B, Go M, Lau J, Spencer S, Raab H, Soriano R, Jhunjhunwala S, Cohen R, Caruso M, Polakis P, Flygare J, Polson AG
Clin Cancer Res (2015), 21(14), 3298-306
View abstract on PubMed

Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers
Dal Corso A, Caruso M, Belvisi L, Arosio D, Piarulli U, Albanese C, Gasparri F, Marsiglio A, Sola F, Troiani S, Valsasina B, Pignataro L, Donati D, Gennari C.
Chemistry (2015), 21(18), 6921-9
View abstract on PubMed

Targeting MPS1 enhances radiosensitization of human glioblastoma by modulating DNA repair proteins
Maachani UB, Kramp T, Hanson R, Zhao S, Celiku O, Shankavaram U, Colombo R, Caplen NJ, Camphausen K, Tandle A
Mol Cancer Res. 2015 May;13(5):852-62. doi: 10.1158/1541-7786.MCR-14-0462-T. Epub 2015 Feb 26
View abstract on PubMed

Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
Pellegatta S1, Valletta L, Corbetta C, Patanè M, Zucca I, Riccardi Sirtori F, Bruzzone MG, Fogliatto G, Isacchi A, Pollo B, Finocchiaro G.
Acta Neuropathol Commun (2015), 3(1),180
View abstract on PubMed

Mcl-1 antagonism Is a potential therapeutic strategy in a subset of solid cancers
Modugno M, Banfi P, Gasparri F, Borzilleri R, Carter P, Cornelius L, Gottardis M, Lee V, Mapelli C, Naglich JG, Tebben A, Vite G, Pastori W, Albanese C, Corti E, Ballinari D, Galvani A
Exp Cell Res (2015), 332(2), 267-77
View abstract on PubMed

Optimization of Diarylthiazole B-Raf Inhibitors: Identification of a Compound Endowed with High Oral Antitumor Activity, Mitigated hERG Inhibition, and Low Paradoxical Effect
Pulici M, Traquandi G, Marchionni C, Modugno M, Lupi R, Amboldi N, Casale E, Colombo N, Corti L, Fasolini M, Gasparri F, Pastori W, Scolaro A, Donati D, Felder E, Galvani A, Isacchi A, Pesenti E, Ciomei M.
ChemMedChem (2015), 10(2), 276-95
View abstract on PubMed